Literature DB >> 32182382

Combination therapy with acitretin and glycyrrhizin in generalized pustular psoriasis with liver test abnormalities: A case series.

Ning Yu1,2, Ying Li1,2, Yangfeng Ding1,2, Yuling Shi1,2.   

Abstract

Liver test abnormalities (LTA) are a frequent extracutaneous manifestation in generalized pustular psoriasis (GPP). Due to possible hepatotoxicity of systemic monotherapy, it is challenging to simultaneously achieve clinical remission and LTA normalization. However, evidence for therapy is lacking. The aim of this study was to assess the effectiveness of combination therapy of acitretin and glycyrrhizin in nine GPP patients with LTA. During the acute phase of GPP, a combination of acitretin (0.5 mg/kg/d PO) and glycyrrhizin (80 mg/d intravenous) was initiated. After 2 weeks, all the patients promptly achieved at least 77% improvement in the severity score of GPP, as well as a significant reduction of liver enzymes. The patients were continuously treated with tapered doses of acitretin (20-30 mg/d PO) and glycyrrhizin (150 mg/d PO), and presented stable conditions during the 12-month follow-up. In conclusion, we consider that the combination of acitretin plus glycyrrhizin is an effective and safe therapy in GPP patients with LTA.
© 2020 Wiley Periodicals LLC.

Entities:  

Keywords:  acitretin; generalized pustular psoriasis; glycyrrhizin; liver test abnormalities

Mesh:

Substances:

Year:  2020        PMID: 32182382     DOI: 10.1111/dth.13318

Source DB:  PubMed          Journal:  Dermatol Ther        ISSN: 1396-0296            Impact factor:   2.851


  2 in total

1.  Comparative Study on the Clinical Efficacy and Safety of Acitretin and MTX in the Treatment of Pustular Psoriasis by TLR7/MyD88/CXCL16 Pathway.

Authors:  Jiajing Lu; Yu Wang; Ying Li; Yu Gong; Yangfeng Ding; Yuling Shi
Journal:  Appl Bionics Biomech       Date:  2022-03-18       Impact factor: 1.781

Review 2.  Research Progress on the Antiviral Activity of Glycyrrhizin and its Derivatives in Liquorice.

Authors:  Changchao Huan; Yao Xu; Wei Zhang; Tingting Guo; Haochun Pan; Song Gao
Journal:  Front Pharmacol       Date:  2021-07-06       Impact factor: 5.810

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.